HK1214355A1 - 用於治療和/或限制糖尿病發展的方法 - Google Patents

用於治療和/或限制糖尿病發展的方法

Info

Publication number
HK1214355A1
HK1214355A1 HK16102230.8A HK16102230A HK1214355A1 HK 1214355 A1 HK1214355 A1 HK 1214355A1 HK 16102230 A HK16102230 A HK 16102230A HK 1214355 A1 HK1214355 A1 HK 1214355A1
Authority
HK
Hong Kong
Prior art keywords
diabetes
treating
methods
limiting development
development
Prior art date
Application number
HK16102230.8A
Other languages
English (en)
Inventor
Per Olof Berggren
Shao-Nian Yang
Original Assignee
Biocrine Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocrine Ab filed Critical Biocrine Ab
Publication of HK1214355A1 publication Critical patent/HK1214355A1/zh

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/507—Pancreatic cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
HK16102230.8A 2012-12-18 2016-02-26 用於治療和/或限制糖尿病發展的方法 HK1214355A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261738835P 2012-12-18 2012-12-18
PCT/EP2013/076917 WO2014095875A1 (en) 2012-12-18 2013-12-17 Methods for treating and/or limiting development of diabetes

Publications (1)

Publication Number Publication Date
HK1214355A1 true HK1214355A1 (zh) 2016-07-22

Family

ID=49876594

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16102230.8A HK1214355A1 (zh) 2012-12-18 2016-02-26 用於治療和/或限制糖尿病發展的方法

Country Status (10)

Country Link
US (1) US9068971B2 (zh)
EP (1) EP2936151B1 (zh)
JP (1) JP6322209B2 (zh)
KR (1) KR102141898B1 (zh)
CN (1) CN105051534B (zh)
DK (1) DK2936151T3 (zh)
ES (1) ES2689922T3 (zh)
HK (1) HK1214355A1 (zh)
PL (1) PL2936151T3 (zh)
WO (1) WO2014095875A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170115035A (ko) 2015-02-09 2017-10-16 바이오크린 에이비 근위축성 측색 경화증을 가진 대상체에서 당뇨병을 치료하고/하거나 당뇨병의 발병을 제한하는 방법
WO2017027973A1 (en) * 2015-08-18 2017-02-23 Novation Pharmaceuticals Inc. Benzopyran derivatives and uses thereof
EP3383869B1 (en) * 2015-11-30 2023-06-28 Merck Sharp & Dohme LLC Aryl sulfonamides as blt1 antagonists
EP3383868B1 (en) * 2015-11-30 2022-10-05 Merck Sharp & Dohme LLC Aryl sulfonamides as blt1 antagonists
DE202017007491U1 (de) * 2016-12-02 2022-01-07 Sophion Bioscience A/S Dichtungsverstärker
CN113967210A (zh) * 2020-07-24 2022-01-25 上海交通大学医学院附属瑞金医院 一种干扰整合素β3/Src相互作用的化合物的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6486299B1 (en) * 1998-09-28 2002-11-26 Curagen Corporation Genes and proteins predictive and therapeutic for stroke, hypertension, diabetes and obesity
JP2002080499A (ja) * 2000-09-01 2002-03-19 Suntory Ltd カルシウムチャンネル阻害作用を有する新規ペプチド
JP2006515274A (ja) 2002-10-08 2006-05-25 マサチューセッツ・インスティテュート・オブ・テクノロジー コレステロール輸送の調節のための化合物
ATE409046T1 (de) * 2003-03-12 2008-10-15 Rappaport Family Inst For Res Zusammensetzungen und verfahren zur diagnose und behandlung einer entzündung
PL1623228T3 (pl) * 2003-04-29 2013-04-30 Biocrine Ab APOCIII i leczenie oraz diagnozowanie cukrzycy
KR20140106761A (ko) * 2005-09-16 2014-09-03 코넬 리서치 화운데이션,인크. Ｃｄ36 발현을 감소시키는 방법
WO2009128734A1 (en) * 2008-04-18 2009-10-22 Vialactia Biosciences (Nz) Limited Marker assisted identification of mammals for desired phenotypic trait
US8557513B2 (en) * 2011-06-27 2013-10-15 Biocrine Ab Methods for treating and/or limiting development of diabetes

Also Published As

Publication number Publication date
DK2936151T3 (en) 2018-08-27
CN105051534A (zh) 2015-11-11
JP2016510210A (ja) 2016-04-07
KR102141898B1 (ko) 2020-08-06
PL2936151T3 (pl) 2018-11-30
WO2014095875A1 (en) 2014-06-26
EP2936151A1 (en) 2015-10-28
US9068971B2 (en) 2015-06-30
KR20150096676A (ko) 2015-08-25
EP2936151B1 (en) 2018-07-18
CN105051534B (zh) 2017-08-18
ES2689922T3 (es) 2018-11-16
US20140170113A1 (en) 2014-06-19
JP6322209B2 (ja) 2018-05-09

Similar Documents

Publication Publication Date Title
EP2675459A4 (en) COMPOUNDS AND METHODS FOR TREATING DIABETES
HK1251796A1 (zh) 治療糖尿病的方法和組合物
HK1208439A1 (zh) -氮雜吲唑化合物及其使用方法
EP2887805A4 (en) COMPOUNDS AND METHOD FOR TREATING BLOOD HIGH PRESSURE
HK1204450A1 (zh) 治療腹腔疾病的方法
HK1209633A1 (zh) 治療糖尿病的組合物和方法
EP2874647A4 (en) METHOD FOR DIAGNOSIS AND TREATMENT
HK1200348A1 (zh) 用於治療龐貝氏症的方法和材料
EP2867239A4 (en) OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES
HK1214355A1 (zh) 用於治療和/或限制糖尿病發展的方法
GB201217296D0 (en) Method of treatment and/or prevention
EP2888370A4 (en) DIAGNOSIS, FORECASTING AND TREATMENT PROCEDURES
EP2836804A4 (en) DEVICE AND METHOD FOR DETERMINING SAFE TANNING TIME
IL234606B (en) Innovative methods and compounds for the treatment of diseases
EP2804614A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES AND / OR ADIPOSITAS
ZA201501503B (en) Bio-inoculant and use thereof for treatment of effluents
HK1210077A1 (zh) 治療或預防呼吸狀態的方法
HK1206791A1 (zh) 用於乙型肝炎治療的反應預測的裝置和方法
HK1212999A1 (zh) 用於治療和/或限制糖尿病的發展的方法
ZA201408065B (en) Compositions and methods for the treatment of diabetes
EP2864417A4 (en) POLYMER AND METHOD OF USE
HK1202819A1 (zh) 型和 型糖尿病的治療
HK1223034A1 (zh) 用於治療 型糖尿病的方法和養生方案
GB201221032D0 (en) Method of treatment
GB201207894D0 (en) Method of treatment